Is Beam Therapeutics profitable in 2026?

No. Beam reported a FY2025 operating loss of $383.7 million and an accumulated deficit of $1.6 billion as of February 24, 2026. It remains pre-commercial with no approved products, funded by $1.2 billion in cash as of March 31, 2026, with runway guided into mid-2029.

Has Beam Therapeutics had layoffs?

Yes. In October 2023 Beam cut about 20% of staff, roughly 100 positions, to focus R&D on sickle cell disease and AATD and extend cash runway. Headcount has since recovered to approximately 536 employees as of December 2025, up 6.2% year-over-year.

Could AI replace Beam Therapeutics' drug development work?

Unlikely for its core moat. Beam's value rests on wet-lab clinical trials, GMP manufacturing, and regulatory filings, not AI-substitutable tasks. AI-driven platforms like Lila Sciences are compressing adjacent preclinical discovery timelines as of July 2026, but do not directly threaten Beam's late-stage clinical and manufacturing barriers.

Who is Beam Therapeutics' biggest competitor?

CRISPR Therapeutics, via its Casgevy therapy co-developed with Vertex Pharmaceuticals, is Beam's most direct threat since Casgevy is already FDA-approved and commercial for sickle cell disease as of 2026, while Beam's risto-cel remains pre-commercial with a BLA targeted for year-end 2026.

Who owns Beam Therapeutics?

Beam Therapeutics is a publicly traded company on Nasdaq under ticker BEAM, founded in 2017 with roots in the Broad Institute of MIT and Harvard and co-founders David R. Liu and Feng Zhang. It has no corporate parent; market cap was approximately $2.74 billion as of July 23, 2026.

What is Beam Therapeutics' main product and when will it launch?

Risto-cel, a base-edited cell therapy for severe sickle cell disease, is Beam's lead program. A BLA submission is targeted as early as year-end 2026, pending final 15-month BEACON follow-up safety and durability data, per the company's May 7, 2026 financial results.

Pharma and healthcare groups · United States

Beam Therapeutics

beamtx.com ↗

Biotech using base editing to build one-time gene therapies, led by risto-cel for sickle cell disease.

Losing its protection

Assessed 24 July 2026 · Evidence as of 24 July 2026

The structural protection is eroding.

On the recordSince 24 July 2026 · Checkable from year-end 2026 · Every call on the record Checkpoint: Risto-cel BLA submission pending final 15-month BEACON follow-up safety and durability data

The call

Beam has strong patent protection and cash runway, but its main product is still unapproved while Vertex's Casgevy already treats patients in the same disease.

Beam Therapeutics uses base-editing technology to fix genetic diseases like sickle cell disease. The main challenge is that Vertex and CRISPR Therapeutics already have an approved competitor called Casgevy on the market, and early sales have been slower than expected even at $2 to $3 million per patient. Beam's shot at success hinges almost entirely on whether the FDA approves its own sickle cell drug by the end of 2026 and whether patients actually choose it over Casgevy, which is an open question in a market where uptake has been tougher than early backers hoped.

Why

AI pressure: Lila Sciences and other AI-driven self-driving lab platforms. AI platforms speed up early drug discovery but don't touch Beam's late-stage trials, FDA process, or manufacturing setup. Could AI do the core job? Unlikely.

Bigger players: Vertex Pharmaceuticals (Casgevy, co-developed with CRISPR Therapeutics). Casgevy is already FDA-approved and selling into the same sickle cell disease market Beam's risto-cel hasn't entered yet. Could a giant copy it? No, they are blocked.

What protects it. Exclusive Broad Institute base-editing license with patents to 2039-2046, RMAT and Orphan Drug status, and $1.2B cash lasting into mid-2029.

What would change this call

Beam submits risto-cel BLA by year-end 2026 as targeted. Shows the SCD program is on track to compete with Casgevy rather than slipping further behind.
Casgevy patient starts and revenue figures reported by Vertex through 2026. Indicates how much of the SCD market is being locked up before risto-cel can launch.
15-month BEACON follow-up safety and durability data released. Reveals whether risto-cel's efficacy holds up or a safety signal emerges that delays approval.

Key numbers

$1.2B cash on hand, runway guided into mid-2029 (2026-05-07)
BEACON trial: 31 patients, over 60% fetal hemoglobin (2025-12-06)
Base-editing patents run through 2039 to 2046 (2026-02-24)

Named risks

Risto-cel BLA submission could slip past year-end 2026 target pending 15-month BEACON follow-up data. Severity: high
Safety signal could emerge in extended BEACON follow-up before submission. Severity: high
Casgevy and Lyfgenia could lock up sickle cell market before risto-cel launch, given slow patient starts industry-wide despite $2-3M pricing. Severity: medium
Continued substantial operating losses ($383.7M in FY2025) with no approved products generating revenue. Severity: medium
AI-accelerated preclinical discovery platforms could compress competitors' timelines in adjacent gene-editing R&D. Severity: low

Rivals, as read in July 2026

Rival	Direction	Evidence
CRISPR Therapeutics / Vertex (Casgevy)	losing to	Casgevy already FDA-approved and commercial for sickle cell disease as of July 2026, while risto-cel BLA still targeted for year-end 2026
bluebird bio (Lyfgenia)	gaining on	Lyfgenia reportedly lost commercial momentum after 2025 safety black-box warnings, per March 2026 report
Intellia Therapeutics	contesting	Intellia leads in vivo CRISPR programs like ATTR amyloidosis, a parallel gene-editing race as of 2026
Verve Therapeutics (acquired by Eli Lilly)	gaining on	Verve licensed Beam's base-editing IP then was acquired by Eli Lilly, per November 2025 report, validating Beam's IP value
Lila Sciences (AI self-driving lab)	contesting	Reportedly replicated a complex CAR-T program in about 6 months versus 5 years and $100M+, per July 16, 2026 report

Questions people ask

Is Beam Therapeutics profitable in 2026?: No. Beam reported a FY2025 operating loss of $383.7 million and an accumulated deficit of $1.6 billion as of February 24, 2026. It remains pre-commercial with no approved products, funded by $1.2 billion in cash as of March 31, 2026, with runway guided into mid-2029.
Has Beam Therapeutics had layoffs?: Yes. In October 2023 Beam cut about 20% of staff, roughly 100 positions, to focus R&D on sickle cell disease and AATD and extend cash runway. Headcount has since recovered to approximately 536 employees as of December 2025, up 6.2% year-over-year.
Could AI replace Beam Therapeutics' drug development work?: Unlikely for its core moat. Beam's value rests on wet-lab clinical trials, GMP manufacturing, and regulatory filings, not AI-substitutable tasks. AI-driven platforms like Lila Sciences are compressing adjacent preclinical discovery timelines as of July 2026, but do not directly threaten Beam's late-stage clinical and manufacturing barriers.
Who is Beam Therapeutics' biggest competitor?: CRISPR Therapeutics, via its Casgevy therapy co-developed with Vertex Pharmaceuticals, is Beam's most direct threat since Casgevy is already FDA-approved and commercial for sickle cell disease as of 2026, while Beam's risto-cel remains pre-commercial with a BLA targeted for year-end 2026.
Who owns Beam Therapeutics?: Beam Therapeutics is a publicly traded company on Nasdaq under ticker BEAM, founded in 2017 with roots in the Broad Institute of MIT and Harvard and co-founders David R. Liu and Feng Zhang. It has no corporate parent; market cap was approximately $2.74 billion as of July 23, 2026.
What is Beam Therapeutics' main product and when will it launch?: Risto-cel, a base-edited cell therapy for severe sickle cell disease, is Beam's lead program. A BLA submission is targeted as early as year-end 2026, pending final 15-month BEACON follow-up safety and durability data, per the company's May 7, 2026 financial results.

Timeline

2026-07-07H.C. Wainwright reiterates Buy rating, $80 price target, on risto-cel BLA progress
2026-05-07Q1 2026 results: $1.2B cash, risto-cel BLA targeted year-end 2026, BEAM-302 pivotal cohort planned H2 2026
2026-04-01BEACON sickle cell trial data published in New England Journal of Medicine
2026-02-25Pfizer exercises exclusive worldwide license on Beam liver-targeted candidate after collaboration completion
2026-02-24FY2025 10-K: $383.7M operating loss, $1.6B accumulated deficit, $139.7M license revenue, BEAM-304 PKU program announced
2025-12-06Updated BEACON Phase 1/2 data presented at ASH: 31 patients, over 60% fetal hemoglobin, up to 20.4 months durability
2025-08-14Risto-cel receives FDA RMAT designation for sickle cell disease
2023-10-19Beam cuts about 20% of workforce, roughly 100 positions, to conserve cash
2020-02Beam completes IPO, raising $180 million after nearly $1 billion in prior venture funding

Revision history

24 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

Community Health Systems Viatris Accendra Health

More in Pharma and healthcare groups →

Sources

Beam Therapeutics Inc. SEC 10-K Report (2026-02-24)
Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial (2025-12-06)
Beam Therapeutics Publishes Base Editing Clinical Data for Sickle Cell Disease Therapy (2026-04-01)
BEAM-101 Receives RMAT for the Treatment of Sickle Cell Disease (2025-08-14)
EX-99.1 Q1 2026 Financial Results (2026-05-07)
Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results... PKU (2026-02-24)
Beam Therapeutics (BEAM) Earnings Date and Reports 2026 (2026-07-18)
gurufocus.com (2026-07-23)
Beam cuts one in five staffers to conserve cash (2023-10-19)
Beam Therapeutics Number of Employees 2026 (2026-06-29)
After gene therapy exit, Pfizer options Beam gene editing asset (2026-02-25)
Beam Therapeutics' Strategic Position in Base Editing and Pipeline Progress (2025-09-03)